Strategic Advocates’s Novavax NVAX Stock Holding History

Strategic Advocates’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2	Closed	-$13	–	491
2025 Q4	$13	Sell	2 -4	-67%	-$30	﹤0.01%	630
2025 Q3	$52	Buy	+6	New	+$47	﹤0.01%	590

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Strategic Advocates's NVAX Position: Q1 2026 in Review

Strategic Advocates sold out of Novavax (NVAX) in Q1 2026, closing a stake of 2 shares — an estimated $13 sold.

Strategic Advocates first reported a position in NVAX in Q3 2025 and held it in 2 quarters. The position peaked at $52 in Q3 2025. 257 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

Strategic Advocates reported no remaining Novavax position as of Q1 2026 after selling out during the quarter.
Strategic Advocates sold 2 Novavax shares in Q1 2026, an estimated $13.
Strategic Advocates first reported a position in Novavax in Q3 2025 and held it in 2 quarters.
Strategic Advocates's Novavax position peaked at $52 in Q3 2025.
257 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.